These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 36809443)

  • 21. EGFR overexpression increases radiotherapy response in HPV-positive head and neck cancer through inhibition of DNA damage repair and HPV E6 downregulation.
    Alsahafi EN; Thavaraj S; Sarvestani N; Novoplansky O; Elkabets M; Ayaz B; Tavassoli M; Legends MF
    Cancer Lett; 2021 Feb; 498():80-97. PubMed ID: 33137407
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ON 01910.Na (rigosertib) inhibits PI3K/Akt pathway and activates oxidative stress signals in head and neck cancer cell lines.
    Prasad A; Khudaynazar N; Tantravahi RV; Gillum AM; Hoffman BS
    Oncotarget; 2016 Nov; 7(48):79388-79400. PubMed ID: 27764820
    [TBL] [Abstract][Full Text] [Related]  

  • 23. LCL161, a SMAC-mimetic, Preferentially Radiosensitizes Human Papillomavirus-negative Head and Neck Squamous Cell Carcinoma.
    Yang L; Kumar B; Shen C; Zhao S; Blakaj D; Li T; Romito M; Teknos TN; Williams TM
    Mol Cancer Ther; 2019 Jun; 18(6):1025-1035. PubMed ID: 31015310
    [TBL] [Abstract][Full Text] [Related]  

  • 24. AKT inhibition as a strategy for targeting hypoxic HPV-positive HNSCC.
    Göttgens EL; Bussink J; Ansems M; Hammond EM; Span PN
    Radiother Oncol; 2020 Aug; 149():1-7. PubMed ID: 32361013
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Matrix metalloproteinase-2 and -14 in p16-positive and -negative HNSCC after exposure To 5-FU and docetaxel In Vitro.
    Aderhold C; Umbreit C; Faber A; Birk R; Sommer JU; Hörmann K; Schultz JD
    Anticancer Res; 2014 Sep; 34(9):4929-37. PubMed ID: 25202075
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dynamic changes of the EMT spectrum between circulating tumor cells and the tumor microenvironment in human papillomavirus-positive head and neck squamous cell carcinoma.
    Ida S; Takahashi H; Tada H; Mito I; Matsuyama T; Chikamatsu K
    Oral Oncol; 2023 Feb; 137():106296. PubMed ID: 36571985
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Zerumbone acts as a radiosensitizer in head and neck squamous cell carcinoma.
    Schnoell J; Stanisz I; Jank BJ; Stanek V; Schmid R; Brunner M; Heiduschka G; Kotowski U
    Invest New Drugs; 2022 Apr; 40(2):224-231. PubMed ID: 34613571
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TRAF3/CYLD mutations identify a distinct subset of human papillomavirus-associated head and neck squamous cell carcinoma.
    Hajek M; Sewell A; Kaech S; Burtness B; Yarbrough WG; Issaeva N
    Cancer; 2017 May; 123(10):1778-1790. PubMed ID: 28295222
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Unexpected alteration of β-catenin and c-KIT expression by 5-FU and docetaxel in p16-positive squamous cell carcinoma compared to HPV-negative HNSCC cells in vitro.
    Umbreit C; Aderhold C; Faber A; Sommer JU; Sauter A; Hofheinz RD; Stern-Sträter J; Hoermann K; Schultz JD
    Anticancer Res; 2013 Jun; 33(6):2457-65. PubMed ID: 23749896
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HS-173, a selective PI3K inhibitor, induces cell death in head and neck squamous cell carcinoma cell lines.
    Foki E; Stanisz I; Kadletz L; Kotowski U; Seemann R; Schmid R; Heiduschka G
    Wien Klin Wochenschr; 2021 Jan; 133(1-2):26-31. PubMed ID: 32876741
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification and validation of a prognostic signature of autophagy, apoptosis and pyroptosis-related genes for head and neck squamous cell carcinoma: to imply therapeutic choices of HPV negative patients.
    Nan Z; Dou Y; Chen A; Wang K; Sun J; Meng Z; Neckenig M; Ai D; Liu S; Dong Z; Ma C; Cheng Y; Qu X
    Front Immunol; 2022; 13():1100417. PubMed ID: 36703967
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel splice variant of LOXL2 promotes progression of human papillomavirus-negative head and neck squamous cell carcinoma.
    Liu C; Guo T; Sakai A; Ren S; Fukusumi T; Ando M; Sadat S; Saito Y; Califano JA
    Cancer; 2020 Feb; 126(4):737-748. PubMed ID: 31721164
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chemotherapeutic alteration of β-catenin and c-kit expression by imatinib in p16-positive squamous cell carcinoma compared to HPV-negative HNSCC cells in vitro.
    Schultz JD; Sommer JU; Hoedt S; Erben P; Hofheinz RD; Faber A; Thorn C; Hörmann K; Sauter A
    Oncol Rep; 2012 Jan; 27(1):270-80. PubMed ID: 21993766
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Notch inhibitor, FLI-06, increases the chemosensitivity of head and neck Squamous cell carcinoma cells to taxanes-based treatment.
    Czerwonka A; Kałafut J; Wang S; Anameric A; Przybyszewska-Podstawka A; Toriseva M; Nees M
    Biomed Pharmacother; 2024 Aug; 177():116822. PubMed ID: 38906029
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Palbociclib Renders Human Papilloma Virus-Negative Head and Neck Squamous Cell Carcinoma Vulnerable to the Senolytic Agent Navitoclax.
    Gadsden NJ; Fulcher CD; Li D; Shrivastava N; Thomas C; Segall JE; Prystowsky MB; Schlecht NF; Gavathiotis E; Ow TJ
    Mol Cancer Res; 2021 May; 19(5):862-873. PubMed ID: 33495400
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Different Impacts of DNA-PK and mTOR Kinase Inhibitors in Combination with Ionizing Radiation on HNSCC and Normal Tissue Cells.
    Klieber N; Hildebrand LS; Faulhaber E; Symank J; Häck N; Härtl A; Fietkau R; Distel LV
    Cells; 2024 Feb; 13(4):. PubMed ID: 38391917
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Death agonist antibody against TRAILR2/DR5/TNFRSF10B enhances birinapant anti-tumor activity in HPV-positive head and neck squamous cell carcinomas.
    An Y; Jeon J; Sun L; Derakhshan A; Chen J; Carlson S; Cheng H; Silvin C; Yang X; Van Waes C; Chen Z
    Sci Rep; 2021 Mar; 11(1):6392. PubMed ID: 33737574
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Demethylation Therapy as a Targeted Treatment for Human Papillomavirus-Associated Head and Neck Cancer.
    Biktasova A; Hajek M; Sewell A; Gary C; Bellinger G; Deshpande HA; Bhatia A; Burtness B; Judson B; Mehra S; Yarbrough WG; Issaeva N
    Clin Cancer Res; 2017 Dec; 23(23):7276-7287. PubMed ID: 28916527
    [No Abstract]   [Full Text] [Related]  

  • 39. mTOR inhibition as an adjuvant therapy in a metastatic model of HPV+ HNSCC.
    Coppock JD; Vermeer PD; Vermeer DW; Lee KM; Miskimins WK; Spanos WC; Lee JH
    Oncotarget; 2016 Apr; 7(17):24228-41. PubMed ID: 27015118
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BCCIPβ facilitates p53 ubiquitination via binding with E6 protein in high-risk HPV positive head and neck squamous cell carcinoma.
    Wang F; Wang J; Wang J; Zhang L; Fu H; Li J; Tian T; Zuo J; Lv W; Ma X
    Biochem Biophys Res Commun; 2020 Aug; 529(3):685-691. PubMed ID: 32736693
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.